These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Yilmaz M, Isaoglu U, Delibas IB, Kadanali S. J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088 [Abstract] [Full Text] [Related]
6. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Pehlivanov B, Orbetzova M. Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429 [Abstract] [Full Text] [Related]
7. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA, Shin SY, Yoon BK, Choi D. Gynecol Endocrinol; 2007 Oct; 23(8):461-7. PubMed ID: 17852414 [Abstract] [Full Text] [Related]
8. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Lankarani M, Valizadeh N, Heshmat R, Peimani M, Sohrabvand F. Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403 [Abstract] [Full Text] [Related]
9. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S243-6. PubMed ID: 17610984 [Abstract] [Full Text] [Related]
10. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Wu J, Zhu Y, Jiang Y, Cao Y. Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522 [Abstract] [Full Text] [Related]
11. Body fat composition and distribution in women with polycystic ovary syndrome. Cosar E, Uçok K, Akgün L, Köken G, Sahin FK, Arioz DT, Baş O. Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379 [Abstract] [Full Text] [Related]
12. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance]. Wan DH, Fan P, Bai H, Song Q, Liu HW. Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923 [Abstract] [Full Text] [Related]
13. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population]. Kavardzhikova S, Pechlivanov B. Akush Ginekol (Sofiia); 2010 Jan; 49(4):32-7. PubMed ID: 20734639 [Abstract] [Full Text] [Related]
14. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Pehlivanov B, Mitkov M. Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711 [Abstract] [Full Text] [Related]
17. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Toscani MK, Mario FM, Radavelli-Bagatini S, Spritzer PM. Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313 [Abstract] [Full Text] [Related]
18. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. Thomann R, Rossinelli N, Keller U, Tirri BF, De Geyter C, Ruiz J, Kränzlin M, Puder JJ. Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906 [Abstract] [Full Text] [Related]